このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Gossamer Bio 過去の業績

過去基準チェック /06

Gossamer Bioの収益は年平均-1.8%で減少しているが、Biotechs業界はgrowingで15.5%年平均の収益となった。

主要情報

-1.8%

収益成長率

28.1%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	n/a
株主資本利益率	-645.8%
ネット・マージン	n/a
前回の決算情報	31 Mar 2024

Recent updates

収支内訳

Gossamer Bio の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:GOSS 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
31 Mar 24	-173	38	130
31 Dec 23	-180	38	135
30 Sep 23	-187	42	147
30 Jun 23	-207	44	160
31 Mar 23	-221	46	166
31 Dec 22	-229	48	171
30 Sep 22	-230	43	170
30 Jun 22	-231	44	169
31 Mar 22	-234	44	171
31 Dec 21	-234	46	170
30 Sep 21	-242	51	168
30 Jun 21	-240	50	167
31 Mar 21	-247	50	161
31 Dec 20	-243	50	161
30 Sep 20	-233	45	165
30 Jun 20	-224	44	163
31 Mar 20	-202	42	160
31 Dec 19	-180	39	143
30 Sep 19	-164	41	127
30 Jun 19	-165	55	105
31 Mar 19	-154	49	78
31 Dec 18	-147	44	55
30 Sep 18	-115	30	30
30 Jun 18	-66	7	11
31 Mar 18	-33	3	4
31 Dec 17	-7	0	1

質の高い収益: GOSSは現在利益が出ていません。

利益率の向上: GOSSは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: GOSSは利益が出ておらず、過去 5 年間で損失は年間1.8%の割合で増加しています。

成長の加速: GOSSの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: GOSSは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: GOSSは現在利益が出ていないため、自己資本利益率 ( -645.83% ) はマイナスです。

Gossamer Bio 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Gossamer Bio, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Gossamer Bio, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Gossamer Bio, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Recent updates

Gossamer Bio, Inc. Receives A Written Notice from the Staff Regarding Minimum Bid Price Requirement

Gossamer Bio, Inc., Annual General Meeting, Jun 06, 2024

Gossamer Bio Announces Board of Directors Appointments

Price target increased by 15% to US$6.09

Gossamer Bio Inc. Appoints Bob Smith as Chief Commercial Officer

Gossamer Bio, Inc. Appoints John Quisel to Its Board of Directors

Gossamer Bio, Inc. Appoints John Quisel to Its Board of Directors

COO & CFO recently bought US$113k worth of stock

Gossamer Bio Receives Non-Compliance Notice from Nasdaq

Gossamer Bio Receives Non-Compliance Notice from Nasdaq

Gossamer Bio, Inc. Announces Resignation of Kristina Burow from the Board of Directors

Price target decreased by 13% to US$5.18

Price target decreased by 7.9% to US$5.85

Gossamer Bio, Inc. announced that it has received $211.849524 million in funding from a group of investors

New major risk - Shareholder dilution

New major risk - Share price stability

Price target decreased by 7.2% to US$7.05

Price target increased by 14% to US$8.20

Gossamer Bio, Inc., Annual General Meeting, Jun 08, 2023

COO & CFO recently bought US$56k worth of stock

Co-Founder recently bought US$1.0m worth of stock

Price target decreased to US$13.00

Gossamer Bio, Inc. Announces Seralutinib Meets Primary Endpoint in Phase 2 Torrey Study in PAH

Insufficient new directors

Chief Scientific Officer recently sold US$59k worth of stock

Peaking Back In On Gossamer Bio

Price target increased to US$18.64

Price target increased to US$18.10

Price target increased to US$17.60

Gossamer Bio, Inc. announced that it has received $120.041922 million in funding from a group of investors

Gossamer Bio, Inc. announced that it expects to receive $120.041922 million in funding from a group of investors

Gossamer Bio to raise $120M in a private equity placement

Chief Scientific Officer recently sold US$73k worth of stock

Health Check: How Prudently Does Gossamer Bio (NASDAQ:GOSS) Use Debt?

Price target decreased to US$15.80

Insufficient new directors

Gossamer Bio, Inc. Announces Topline Results from its Phase 2 SHIFT-UC Study Clinical Trial Studying GB004 in Patients

Co-Founder recently sold US$170k worth of stock

Insider recently sold US$52k worth of stock

Insider recently sold US$52k worth of stock

Insider recently sold US$52k worth of stock

Gossamer Bio, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Gossamer Bio (NASDAQ:GOSS) Has Debt But No Earnings; Should You Worry?

Price target increased to US$21.25

Insufficient new directors

Price target increased to US$19.50

Is Gossamer Bio (NASDAQ:GOSS) A Risky Investment?

Price target decreased to US$19.00

Gossamer Bio, Inc.(NasdaqGS:GOSS) dropped from Russell 2500 Growth Index

Chief Scientific Officer has left the company

Chief Scientific Officer recently sold US$52k worth of stock

Chief Scientific Officer recently sold US$52k worth of stock

Gossamer Bio, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Need To Know: Gossamer Bio, Inc. (NASDAQ:GOSS) Insiders Have Been Buying Shares

Gossamer Bio, Inc. Announces Executive Changes

Gossamer Bio (GOSS) Investor Presentation - Slideshow

Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer

Gossamer Bio, Inc. Provides Clinical-Stage Product Candidate Updates

Gossamer Bio, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: US$8.93

Co-Founder & Chairman recently bought US$1m worth of stock

Gossamer Bio, Inc. Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis

Price target lowered to US$26.13

New 90-day low: US$10.09

Gossamer Bio Announces Presentation of GB004 Phase 1b Clinical Data at United European Gastroenterology Virtual Week 2020 and Additional Program Updates

New 90-day low: US$11.30

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

過去基準チェック /06